It is the first time the Office of National Drug Control Policy has given a substance this designation, Rahul Gupta, MD, the office’s director, said during a White House press briefing.
Deaths involving non-opiate xylazine “increased by 1,127 percent in the South, 750 percent in the West, more than 500 percent in the Midwest and more than 100 percent in the Northeast,” according to the briefing.
The mix is also known as “tranq” because the second drug is an animal tranquilizer, and physicians have reported struggles in treating patients who take the laced opioid because naloxone — a popular drug used to reverse opioid overdoses that recently was granted over-the-counter status — is ineffective against fentanyl-xylazine.
Following the emerging threat declaration, the administration said it is working on a “whole-of-government response that includes evidence-based prevention, treatment and supply reduction.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.